Skip navigation
Skip navigation
You are using an outdated browser. Please upgrade your browser.
Professor Max Crispin

Charity Against Breast Cancer announced this week an 11 year £2.25million investment at University of Southampton for the purpose of undertaking research into secondary spread, the main cause of breast cancer related deaths.

The project, led by Professor Max Crispin is exploring innovative ways to develop anti-cancer antibodies that can detect and destroy breast cancer cells, including secondary breast cancer, without damaging surrounding healthy tissue.

To celebrate, an open day held for volunteers and supporters of the charity took place on Monday 1 April at the new Centre for Cancer Immunology building and include talks be led by the researchers involved, tours of the laboratories and a chance for supporters to chat with the research team to see how the funds they have raised are being put to use.

Max Crispin, Professor of Glycobiology at the University of Southampton described the relationship between the charity and University;

“Against Breast Cancer is a remarkable charity. They realise the need for long term support for challenging research programmes and our relationship has been cemented further by the charity’s continuing commitment to fund breast cancer research well into the future.”


Against Breast Cancer
Against Breast Cancer is a charity dedicated to funding ground-breaking research to increase survival after a breast cancer diagnosis by focusing on secondary spread, the cause of all breast-cancer related deaths. We fund research that addresses critical gaps in scientific resources and knowledge to help doctors diagnose and treat secondary breast cancer faster and more effectively, and to understand factors that may increase or reduce the risk of secondary spread so that people can make informed diet and lifestyle choices.
We have directly funded the collection of, and continue to fund the storage of over 23,000 blood and urine samples, provided annually by over 3,300 women with breast cancer from 56 hospitals across the UK in our Diet & Lifestyle Study, the largest national study of its kind. Researchers can determine differences between women who develop secondary breast cancer and those who do not by studying this collection of biological samples and dietary and lifestyle information provided at the same time.

Robert Fleming, Head of Development
T: 01235 858298 M: 07928423348

Our other social media platforms can be sent if pertinent.

This press release was distributed by ResponseSource Press Release Wire on behalf of Against Breast Cancer in the following categories: Health, Women's Interest & Beauty, Medical & Pharmaceutical, Public Sector, Third Sector & Legal, for more information visit